1 09, 2020 Roberta Minari et. al., Detection of EGFR-Activating and T790M Mutations by Liquid Biopsy in Patients with EGFR-Mutated Non-Small-Cell Lung Cancer Who Have Progressed to First- and Second-Generation Tyrosine Kinase Inhibitors: A Multicenter Real-Life Retrospective Study Diatech Pharmacogenetics2020-11-03T15:51:44+01:00 Read More
26 03, 2018 Roberta Minari et. al, Concurrent acquired BRAF V600E mutation and MET amplification as resistance mechanism of first-line osimertinib treatment in NSCLC EGFR-mutated patient. Diatech Pharmacogenetics2018-04-12T14:59:44+02:00 Read More
21 11, 2017 Roberta Minari et. al, Primary resistance to osimertinib due to SCLC transformation: Issue of T790M determination on liquid re-biopsy Diatech Pharmacogenetics2018-01-30T10:43:35+01:00 Read More